Lymphoma, T-Cell, Peripheral

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Alemtuzumab and CHOP in T-cell Lymphoma

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)